AstraZeneca Income Statement
View: Annual
| Dec 08 | Dec 07 | Dec 06 | |
|---|---|---|---|
| Revenue | 31,601.0 | 29,559.0 | 26,475.0 |
| Cost of Goods Sold | 6,598.0 | 6,419.0 | 5,559.0 |
| Gross Profit | 25,003.0 | 23,140.0 | 20,916.0 |
| Gross Profit Margin | 79.1% | 78.3% | 79.0% |
| SG&A Expense | 11,204.0 | 10,364.0 | 9,096.0 |
| Depreciation & Amortization | 2,620.0 | 1,856.0 | 1,345.0 |
| Operating Income | 9,998.0 | 9,053.0 | 9,104.0 |
| Operating Margin | 31.6% | 30.6% | 34.4% |
| Nonoperating Income | 0.0 | 0.0 | 0.0 |
| Nonoperating Expenses | (463.0) | -- | -- |
| Income Before Taxes | 8,681.0 | 7,983.0 | 8,543.0 |
| Income Taxes | 2,551.0 | 2,356.0 | 2,480.0 |
| Net Income After Taxes | 6,130.0 | 5,627.0 | 6,063.0 |
| Continuing Operations | 6,130.0 | 5,595.0 | 6,043.0 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 6,130.0 | 5,595.0 | 6,043.0 |
| Total Net Income | 6,130.0 | 5,595.0 | 6,043.0 |
| Net Profit Margin | 19.4% | 18.9% | 22.8% |
| Diluted EPS from Total Net Income ($) | 4.20 | 14.92 | 3.85 |
| Dividends per Share | 1.90 | 1.75 | 1.41 |
© 2009 Morningstar, Inc. Financial Data provided by
